OSI Adds Liposomal Lurtotecan To Pipeline As Part Of Gilead Oncology Deal
Executive Summary
The topoisomerase I inhibitor NX211 is the most advanced drug candidate OSI Pharmaceuticals will add through its acquisition of Gilead's oncology research program